Anadys Pharmaceuticals Announces Exclusive Collaboration With Novartis to Develop and Commercialize ANA975 and Additional TLR7-Based Therapeutics for Hepatitis C and Hepatitis B
San Diego, California (ots/PRNewswire) - - Total Partnership Valued at Up to USD$570 Million in Upfront and Potential Milestone Payments Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has entered into an exclusive global license and co-development agreement with Novartis to develop, ...
mehr